← Human Trials & Peer-Reviewed Studies
Growth hormone, insulin-like growth factor-1 and insulin resistance in cirrhosis
Plain-language guide to PMID 7904978 (1994): randomized controlled trial study of IGF-1 LR3 and Somatostatin, insulin resistance, prediabetes & type 2 diabetes.
Key Facts
- PMID
- 7904978
- Journal
- Hepatology (Baltimore, Md.)
- Year
- 1994
- Study type
- Randomized Controlled Trial
- Authors
- Shmueli E et al. (4 authors)
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of IGF-1 LR3 and Somatostatin in the context of insulin resistance, prediabetes & type 2 diabetes, published as a randomized controlled trial.
Cirrhosis is characterized by paradoxical growth hormone secretion in response to glucose and insulin infusion.
To ascertain whether this abnormality contributes to insulin resistance, euglycemic hyperinsulinemic glucose clamps were performed on six patients with cirrhosis and six normal control subjects.
Who Took Part
PubMed indexes the participants as adults and middle-aged adults, men only.
How the Study Was Run
In design terms this was a randomized study.
Random assignment meant chance, not the researchers, decided who got IGF-1 LR3 and who got the comparison, which limits bias.
What Was Measured
PubMed files the paper under topics including C-Peptide, Calorimetry, Indirect, Fatty Acids, Nonesterified, Glucose, Glucose Clamp Technique, Growth Hormone and Insulin Resistance.
What This Means in Plain Language
The paper is a randomized study of IGF-1 LR3 and Somatostatin in people with insulin resistance, prediabetes & type 2 diabetes.
The publication is from 1994 (Hepatology (Baltimore, Md.)), a journal based in United States.
More context: the IGF-1 LR3 compound page and the Somatostatin compound page, Insulin resistance, prediabetes & type 2 diabetes research.
Our Notes on the Compounds
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
Related Pages
- Insulin resistance, prediabetes & type 2 diabetes research
- IGF-1 LR3 in the library
- Somatostatin in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.